AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23877348 — intervention group
Group type: COMPARATOR
Intervention: lactulose (placebo)
Number of subjects: 120
Study 20608027 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptide indices and oxidative stress assessment in CHF patients
Number of subjects: 52
Study 18184031 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone self-report of medication use
Number of subjects: 566
Study 16494641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate (SA)
Number of subjects: 0
Study 16494641 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 16494641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 16494641 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 14583362 — intervention group
Group type: EXPERIMENTAL
Intervention: Bail-out abciximab
Number of subjects: 1030
Study 14583362 — intervention group
Group type: COMPARATOR
Intervention: Routine upfront abciximab
Number of subjects: 1030
Study 11082370 — intervention group
Group type: EXPERIMENTAL
Intervention: Full sternotomy approach plus CPB (group A)
Number of subjects: 30
Study 11082370 — intervention group
Group type: COMPARATOR
Intervention: Full sternotomy off-pump (group B)
Number of subjects: 30
Study 11082370 — intervention group
Group type: COMPARATOR
Intervention: Limited left anterior thoracotomy off-pump (group C)
Number of subjects: 30
Study 8828546 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID drug challenge
Number of subjects: 240
Study 1447640 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula
Number of subjects: 205
Study 1447640 — intervention group
Group type: COMPARATOR
Intervention: Intact whey‐predominant milk protein formula (Control)
Number of subjects: 205
Study 29901705 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab as first-line treatment
Number of subjects: 290
Study 29901705 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (control)
Number of subjects: 290
Study 27267755 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management and exercise program (PLE(2)NO)
Number of subjects: 0
Study 27267755 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention (control program)
Number of subjects: 0
Study 25129064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 7479
Study 25129064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7479
Study 23672463 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 21
Study 20159311 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable poly-L-lactic acid (PLLA)
Number of subjects: 233
Study 20159311 — intervention group
Group type: COMPARATOR
Intervention: Human-derived collagen
Number of subjects: 233
Study 18242934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care (self-efficacy promotion and medical treatment of vascular risk factors)
Number of subjects: 153
Study 18242934 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study 15908388 — intervention group
Group type: EXPERIMENTAL
Intervention: ICC‐1132/ISA 720 (20 mug)
Number of subjects: 0
Study 15908388 — intervention group
Group type: EXPERIMENTAL
Intervention: ICC‐1132/ISA 720 (50 mug)
Number of subjects: 0
Study 15908388 — intervention group
Group type: EXPERIMENTAL
Intervention: ICC‐1132/ISA 720
Number of subjects: 0
Study 12825333 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined protocol (5 min rest and 5 min self‐selected active recovery)
Number of subjects: 12
Study 12825333 — intervention group
Group type: COMPARATOR
Intervention: Rest protocol (10 min rest in a sitting position)
Number of subjects: 12
Study 10813106 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian electrocautery
Number of subjects: 0
Study 10813106 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin ovulation induction
Number of subjects: 0
Study 9121810 — intervention group
Group type: COMPARATOR
Intervention: Morphine plus placebo (M + P)
Number of subjects: 32
Study 9121810 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus nimodipine (M + N)
Number of subjects: 32
Study 9121810 — intervention group
Group type: COMPARATOR
Intervention: Morphine only (M)
Number of subjects: 32
Study 9121810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg every 8 h)
Number of subjects: 32
Study 1504891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 10 micrograms
Number of subjects: 16
Study 1504891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 200 micrograms
Number of subjects: 16
Study 1504891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6237209 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeded Dacron grafts
Number of subjects: 161
Study 6237209 — intervention group
Group type: COMPARATOR
Intervention: Unseeded Dacron grafts
Number of subjects: 161
Study 6237209 — intervention group
Group type: COMPARATOR
Intervention: Vein grafts
Number of subjects: 161
Study 31236471 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-Up Sleep (HUS) at greater than 45°
Number of subjects: 88
Study 31236471 — intervention group
Group type: COMPARATOR
Intervention: Head-Down Sleep (HDS)
Number of subjects: 88
Study 31236471 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-Up Sleep (HUS)
Number of subjects: 88
Study 30372482 — intervention group
Group type: EXPERIMENTAL
Intervention: SER (50 to 200 mg/d) + GCBT
Number of subjects: 147
Study 30372482 — intervention group
Group type: EXPERIMENTAL
Intervention: SER + GPT
Number of subjects: 147
Study 30372482 — intervention group
Group type: EXPERIMENTAL
Intervention: SER + GCBT
Number of subjects: 147
Study 30372482 — intervention group
Group type: EXPERIMENTAL
Intervention: SER
Number of subjects: 147
Study 30372482 — intervention group
Group type: COMPARATOR
Intervention: GCBT
Number of subjects: 147
Study 26540600 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 60
Study 26540600 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 60
Study 26540600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham needle acupuncture
Number of subjects: 60
Study 26540600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham laser acupuncture
Number of subjects: 60
Study 26540600 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 60
Study 23955660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PC) intervention
Number of subjects: 332
Study 23955660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 332
Study 23955660 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <40 years
Number of subjects: 332
Study 23955660 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 332
Study 22945620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) for depression, 16 to 20 sessions
Number of subjects: 49
Study 22945620 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 49
Study 19757052 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive implementation support for teachers
Number of subjects: 2983
Study 19757052 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular workshop training only
Number of subjects: 2983
Study 19757052 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 2983
Study 16512088 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg of red vine leaf extract AS 195 twice daily (360 mg in total) for six weeks
Number of subjects: 39
Study 12780674 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (blood concentration 5-10 ng/mL) with MMF and low-dose corticosteroid (stopped after 5 months) and induction with daclizumab
Number of subjects: 82
Study 12780674 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose tacrolimus (blood concentration 10-15 ng/mL) with MMF and standard dose corticosteroid
Number of subjects: 82
Study 10692620 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine sulphate 10 mg
Number of subjects: 10
Study 10692620 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 0.5 mg
Number of subjects: 10
Study 10692620 — intervention group
Group type: EXPERIMENTAL
Intervention: dextropropoxyphene napsylate 100 mg
Number of subjects: 10
Study 10692620 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 9355703 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes erythrocytes
Number of subjects: 0
Study 9355703 — intervention group
Group type: COMPARATOR
Intervention: Control (non-diabetic pregnant women) erythrocytes
Number of subjects: 0
Study 8223138 — intervention group
Group type: COMPARATOR
Intervention: 60 mg levodropropizine
Number of subjects: 10
Study 8223138 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg dropropizine
Number of subjects: 10
Study 8223138 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg levodropropizine
Number of subjects: 10
Study 8223138 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg dropropizine
Number of subjects: 10
Study 8223138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4036849 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation (15,000 IU weekly)
Number of subjects: 109
Study 4036849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 31640645 — intervention group
Group type: EXPERIMENTAL
Intervention: OPAL intervention (community-based, multi-setting, multi-strategy)
Number of subjects: 2611
Study 31640645 — intervention group
Group type: COMPARATOR
Intervention: Matched comparison communities (COMP)
Number of subjects: 2611
Study 31640645 — intervention group
Group type: EXPERIMENTAL
Intervention: OPAL intervention
Number of subjects: 2611
Study 28208190 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 3712
Study 28208190 — intervention group
Group type: COMPARATOR
Intervention: Other atypicals
Number of subjects: 3712
Study 28208190 — intervention group
Group type: COMPARATOR
Intervention: Typical antipsychotics
Number of subjects: 3712
Study 25872943 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) applied to the study group, once a week for the entire period of hospitalization.
Number of subjects: 120
Study 25872943 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment ('soft touch') applied to the sham group, once a week for the entire period of hospitalization.
Number of subjects: 120
Study 25872943 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard medical care only, no additional treatment.
Number of subjects: 120
Study 25872943 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (study, sham, control)
Number of subjects: 120
Study 23531118 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily
Number of subjects: 441
Study 23531118 — intervention group
Group type: COMPARATOR
Intervention: Glipizide 5 mg once daily (titrated to 10 mg if needed)
Number of subjects: 441
Study 21377716 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluticasone furoate and oxymetazoline
Number of subjects: 60
Study 21377716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21377716 — intervention group
Group type: COMPARATOR
Intervention: Oxymetazoline alone
Number of subjects: 60
Study 21377716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Number of subjects: 60
Study 21377716 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 20004289 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 12
Study 20004289 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 12
Study 20004289 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 12
Study 20004289 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 12
Study 20004289 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 12
Study 20004289 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 12
Study 20004289 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 12
Study 17251259 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mitral regurgitation (MR) severity
Number of subjects: 496
Study 17251259 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe MR
Number of subjects: 496
Study 17251259 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of MR during the first post-MI month
Number of subjects: 496
Study 17251259 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of MR over 20 months in survivors
Number of subjects: 496
Study 15159698 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 beta concentration in CSF (Days 8-15 after SAH)
Number of subjects: 0
Study 15159698 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 concentration in CSF (Days 0-3 after SAH)
Number of subjects: 0
Study 15159698 — intervention group
Group type: COMPARATOR
Intervention: Patients without vasospasm and neurological deficits
Number of subjects: 0
Study 12530483 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive oral acyclovir 400 mg three times daily
Number of subjects: 234
Study 12530483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 9814837 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight apo(a) isoforms
Number of subjects: 58
Study 9814837 — intervention group
Group type: EXPERIMENTAL
Intervention: High-molecular-weight apo(a) isoforms
Number of subjects: 58
Study 9814837 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuric patients
Number of subjects: 58
Study 9814837 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58
Study 9814837 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 58
Study 7705112 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin alone (n = 14)
Number of subjects: 45
Study 7705112 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin in combination with rifampin (n = 8)
Number of subjects: 45
Study 7705112 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin in combination with other drugs (aminoglycoside, quinolone, clofazimine, isoniazid, ethambutol, pyrazinamide, minocycline)
Number of subjects: 45
Study 7705112 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (30 mg/kg daily)
Number of subjects: 45
Study 7705112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of clarithromycin
Number of subjects: 45
Study 2552051 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-week career decision-making course
Number of subjects: 42
Study 2552051 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 31121557 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based intervention supported by Internet tools
Number of subjects: 207
Study 31121557 — intervention group
Group type: COMPARATOR
Intervention: Standard letter recommendation
Number of subjects: 207
Study 28460892 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 667
Study 28460892 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 667
Study 28460892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 26049188 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb decontaminate group (15-20 g aqueous extract by gastric tube, enema, or peros, twice a day)
Number of subjects: 57
Study 26049188 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional decontaminate group (glycerine enema or glycerol enema, twice a day)
Number of subjects: 57
Study 26049188 — intervention group
Group type: COMPARATOR
Intervention: Blank control group (no treatment)
Number of subjects: 57
Study 22679301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate (MTX) + sulfasalazine + hydroxychloroquine) with intramuscular glucocorticoids (GCs)
Number of subjects: 281
Study 22679301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with oral GC tapering scheme
Number of subjects: 281
Study 22679301 — intervention group
Group type: COMPARATOR
Intervention: MTX with oral GCs
Number of subjects: 281
Study 21385466 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic therapy (HT) consisting of light physical exercise sessions and a mental stress reduction program administered for two weeks.
Number of subjects: 117
Study 21385466 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) provided to the control group.
Number of subjects: 117
Study 18845781 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed endurance training (SET; n = 9)
Number of subjects: 17
Study 18845781 — intervention group
Group type: COMPARATOR
Intervention: Control (Con; n = 8)
Number of subjects: 17
Study 16915380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.038 mg/kg)
Number of subjects: 28
Study 16915380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15299181 — intervention group
Group type: EXPERIMENTAL
Intervention: RT with DDP (100 mg/m2 on d 2, 22, 42)
Number of subjects: 124
Study 15299181 — intervention group
Group type: EXPERIMENTAL
Intervention: RT with Cb (7 AUC on d 2, 22, 42)
Number of subjects: 124
Study 15299181 — intervention group
Group type: COMPARATOR
Intervention: RT alone (70 Gy)
Number of subjects: 124
Study 11977324 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary gastritis with Helicobacter pylori infection
Number of subjects: 50
Study 11977324 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosive gastritis with Helicobacter pylori infection
Number of subjects: 50
Study 11977324 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary gastritis without Helicobacter pylori infection
Number of subjects: 50
Study 11977324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 11977324 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary gastritis and erosive gastritis
Number of subjects: 50
Study 9043505 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion method
Number of subjects: 118
Study 9043505 — intervention group
Group type: COMPARATOR
Intervention: Midnight removal of the catheter
Number of subjects: 118
Study 9043505 — intervention group
Group type: COMPARATOR
Intervention: Dawn removal of the catheter
Number of subjects: 118
Study 7940136 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5%
Number of subjects: 19
Study 7940136 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 19
Study 3189143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 30
Study 3189143 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 30
Study 31085026 — intervention group
Group type: EXPERIMENTAL
Intervention: Core needle biopsy (CNB) for myxoid tumors
Number of subjects: 369
Study 31085026 — intervention group
Group type: COMPARATOR
Intervention: Core needle biopsy (CNB) for non-myxoid tumors
Number of subjects: 369
Study 28382800 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal application on one side of the pelvis
Number of subjects: 37
Study 25293387 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enalapril at bedtime for 12 weeks
Number of subjects: 24
Study 25293387 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enalapril in the morning for 12 weeks
Number of subjects: 24
Study 22565518 — intervention group
Group type: EXPERIMENTAL
Intervention: Round bur
Number of subjects: 60
Study 22565518 — intervention group
Group type: EXPERIMENTAL
Intervention: Air polishing
Number of subjects: 60
Study 22565518 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion
Number of subjects: 60
Study 22565518 — intervention group
Group type: COMPARATOR
Intervention: Pumice slurry
Number of subjects: 60
Study 22565518 — intervention group
Group type: COMPARATOR
Intervention: Bristle brush
Number of subjects: 60
Study 22565518 — intervention group
Group type: COMPARATOR
Intervention: Longer etching time
Number of subjects: 60
Study 20035531 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anopexy
Number of subjects: 207
Study 20035531 — intervention group
Group type: COMPARATOR
Intervention: Diathermy excision (Milligan‐Morgan haemorrhoidectomy)
Number of subjects: 207
Study 17875033 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressants (4-month prophylactic therapy)
Number of subjects: 45
Study 17875033 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects, N=50)
Number of subjects: 45
Study 15713522 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin 50 mg/m2 days 1, 8 and vinorelbine 25 mg/m2 days 1, 8, 15, 22 for four cycles)
Number of subjects: 424
Study 15713522 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 424
Study 11919666 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administration (25 g)
Number of subjects: 0
Study 11919666 — intervention group
Group type: COMPARATOR
Intervention: Aspartame solution (control)
Number of subjects: 0
Study 10430690 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled laparoscopic TAPP inguinal hernia repair
Number of subjects: 502
Study 10430690 — intervention group
Group type: COMPARATOR
Intervention: Nonstapled laparoscopic TAPP inguinal hernia repair
Number of subjects: 502
Study 7586938 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirin with codeine
Number of subjects: 38
Study 7586938 — intervention group
Group type: EXPERIMENTAL
Intervention: Mersyndol
Number of subjects: 38
Study 7586938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2315472 — intervention group
Group type: EXPERIMENTAL
Intervention: RASE technique
Number of subjects: 20
Study 2315472 — intervention group
Group type: COMPARATOR
Intervention: Conventional SE technique
Number of subjects: 20
Study 7244965 — intervention group
Group type: EXPERIMENTAL
Intervention: Sump drainage
Number of subjects: 0
Study 7244965 — intervention group
Group type: COMPARATOR
Intervention: Closed static drainage
Number of subjects: 0